Amsterdam-based biotech company uniQure sets this share price for €73M public offering: Know more 

Amsterdam-based uniQure, a biotechnology company specialising in human gene-based therapies, recently announced its public offering of 4,411,764 ordinary shares at $17.00 per share.

The expected gross proceeds are around $75M (approximately €73M), before fees and expenses.

All shares will be sold by uniQure, which has also given underwriters a 30-day option to purchase an additional 661,764 shares at the same price.

The offering is expected to close on or about January 10, 2025, subject to the satisfaction of customary closing conditions.

Leerink Partners, Stifel, and Guggenheim Securities are acting as the bookrunning managers for the offering. Chardan and H.C. Wainwright & Co. are acting as the lead managers for the offering.

Partnership with U.S. Food and Drug Administration 

The announcement comes a month after the company reached an agreement with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130.

uniQure is conducting two multi-centre, dose-escalating, Phase I/II clinical studies to explore the safety, tolerability, and exploratory efficacy signals of AMT-130 for the treatment of Huntington’s disease.

In the U.S. study, a total of 26 patients with early manifest Huntington’s disease were randomised to treatment (n=6 low dose; n=10 high dose) or an imitation (sham) surgical procedure (n=10).

Treated patients received a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).

UniQure: Specialising in human gene-based therapies

Based out of Amsterdam, uniQure is a biotechnology company specialising in human gene-based therapies, particularly for severe genetic diseases of the central nervous system (CNS) and liver. 

Leveraging modular and validated technology platforms, the company rapidly advances a proprietary gene therapy pipeline to address critical medical needs

uniQure’s gene therapy for haemophilia B has been approved, which is a significant achievement after over ten years of research and development.

This approval is an important step in genomic medicine and offers a new treatment option for haemophilia patients.

Furthermore, uniQure is working on a range of gene therapies for other serious conditions, including Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and more.